Gotham Asset Management LLC Has $216,000 Position in Immunomedics (IMMU)

Gotham Asset Management LLC trimmed its position in shares of Immunomedics (NASDAQ:IMMU) by 96.4% during the 4th quarter, Holdings Channel reports. The firm owned 13,364 shares of the biopharmaceutical company’s stock after selling 355,931 shares during the quarter. Gotham Asset Management LLC’s holdings in Immunomedics were worth $216,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of IMMU. Palo Alto Investors LLC grew its holdings in Immunomedics by 58.6% during the 4th quarter. Palo Alto Investors LLC now owns 4,774,261 shares of the biopharmaceutical company’s stock valued at $77,152,000 after purchasing an additional 1,763,795 shares during the last quarter. ArrowMark Colorado Holdings LLC grew its holdings in Immunomedics by 48.5% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 5,225,124 shares of the biopharmaceutical company’s stock valued at $84,438,000 after purchasing an additional 1,705,624 shares during the last quarter. Victory Capital Management Inc. bought a new position in Immunomedics during the 4th quarter valued at about $17,941,000. Franklin Resources Inc. bought a new position in Immunomedics in the 4th quarter worth about $12,537,000. Finally, BlackRock Inc. grew its stake in Immunomedics by 8.8% in the 4th quarter. BlackRock Inc. now owns 9,064,259 shares of the biopharmaceutical company’s stock worth $146,478,000 after acquiring an additional 736,608 shares in the last quarter. Institutional investors own 74.51% of the company’s stock.

How to Become a New Pot Stock Millionaire

Shares of IMMU stock opened at $13.94 on Friday. The company has a debt-to-equity ratio of 1.20, a quick ratio of 1.26 and a current ratio of 1.26. The stock has a market capitalization of $2,536.34, a price-to-earnings ratio of -17.21 and a beta of 1.62. Immunomedics has a one year low of $5.00 and a one year high of $18.93.

Immunomedics (NASDAQ:IMMU) last issued its earnings results on Thursday, February 8th. The biopharmaceutical company reported ($0.19) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.09). The business had revenue of $0.60 million for the quarter, compared to analyst estimates of $0.90 million. equities analysts forecast that Immunomedics will post -0.96 EPS for the current fiscal year.

In other news, Director David M. Goldenberg sold 17,729 shares of the stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $17.09, for a total transaction of $302,988.61. Following the transaction, the director now directly owns 1,774,285 shares in the company, valued at $30,322,530.65. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director David M. Goldenberg sold 20,000 shares of the stock in a transaction that occurred on Wednesday, March 7th. The shares were sold at an average price of $17.50, for a total transaction of $350,000.00. Following the transaction, the director now owns 1,774,285 shares in the company, valued at $31,049,987.50. The disclosure for this sale can be found here. Insiders sold a total of 77,729 shares of company stock worth $1,342,589 over the last 90 days. Insiders own 14.80% of the company’s stock.

A number of equities analysts have commented on the stock. Jefferies Group upped their target price on shares of Immunomedics from $22.00 to $27.00 and gave the stock a “buy” rating in a research note on Wednesday, January 24th. BidaskClub upgraded shares of Immunomedics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 25th. ValuEngine upgraded shares of Immunomedics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Zacks Investment Research downgraded shares of Immunomedics from a “hold” rating to a “sell” rating in a research note on Saturday, February 17th. Finally, TheStreet upgraded shares of Immunomedics from a “d” rating to a “c-” rating in a research note on Friday, February 9th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $19.00.

COPYRIGHT VIOLATION WARNING: “Gotham Asset Management LLC Has $216,000 Position in Immunomedics (IMMU)” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/07/gotham-asset-management-llc-has-216000-position-in-immunomedics-immu.html.

Immunomedics Profile

Immunomedics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers.

Want to see what other hedge funds are holding IMMU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunomedics (NASDAQ:IMMU).

Institutional Ownership by Quarter for Immunomedics (NASDAQ:IMMU)

Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply